Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 3,917 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Pulmonary Arterial Hypertension, Right Heart Failure
Interventions: Famotidine 20 MG, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Portopulmonary Hypertension
Interventions: Macitentan, Placebo; Drug · Other
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 29
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more

Conditions: Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome
Interventions: Travatan, Azopt, Alphagan P; Drug
Lead sponsor: Hermann Eye Center; Other
Eligibility: 35 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 21
States / cities: Los Angeles, California • Hamden, Connecticut • Gainesville, Florida + 14 more

Conditions: Hypertension, Elevated Cholesterol, Overweight and Obesity
Interventions: Dietary Intervention; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Treatment-Resistant Hypertension
Interventions: Structured center-based lifestyle intervention, Standard education and physician advice; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 35 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: Gustavo A Heresi, MD, MS; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Baltimore, Maryland • Cleveland, Ohio • Nashville, Tennessee

Conditions: Hypertension
Interventions: Walking Exercise, Nicotinamide Riboside (NR); Behavioral · Drug
Lead sponsor: University of Florida; Other
Eligibility: 55 Years to 105 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cardiovascular Diseases, Cardiovascular Risk Factor, Nutrition Disorders, Diabetes, Hypertension, Cancer, Depression, Obesity, Physical Activity
Interventions: Treatment; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 7 Years to 115 Years
Enrollment: 7,192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Portal Hypertension
Interventions: Particle, Coil; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 22 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension, Diabete Type 2
Interventions: Treatment as Usual Plus Occupational Therapy, Treatment as Usual; Behavioral
Lead sponsor: University of Indianapolis; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Active Control, INV-144; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Garden Grove, California • La Mesa, California • Northridge, California + 15 more

Conditions: Hypertension
Interventions: celecoxib (Celebrex), Placebo; Drug · Other
Lead sponsor: University of Delaware; Other
Eligibility: 22 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Pulmonary Hypertension
Interventions: treprostinil sodium; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension, Neonatal
Interventions: Boppli; Device
Lead sponsor: Indiana University; Other
Eligibility: 0 Months to 9 Months
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sturge Weber Syndrome
Interventions: Everolimus; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 2 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Childhood Obesity, Hypertension, Diabetes, Dyslipidemia
Interventions: Families on Track Intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, NC, North Carolina

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 16
States / cities: Fort Lauderdale, California • Long Beach, California • Roseville, California + 13 more

Conditions: Persistent Fetal Circulation Syndrome
Interventions: Milrinone Lactate; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 10 Days
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Postpartum, Postpartum Depression (PPD), Hypertension Disorders in Pregnancy, Postpartum Anxiety, Postpartum Care, Care Coordination, Care Gaps
Interventions: Postpartum Doula Support in the NICU; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 14
States / cities: Newark, Delaware • Voorhees Township, New Jersey • Bryn Mawr, Pennsylvania + 9 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more

Conditions: Hypertension, Pregnancy Induced
Interventions: Postpartum educational tool after hypertensive pregnancy; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Ocular Hypertension
Interventions: Bimatoprost 0.01%, Bimatoprost 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Artesia, California • El Paso, Texas

Conditions: HIV/AIDS, Diabetes Mellitus, Type 2, Hypertension
Interventions: Medication optimization intervention; Other
Lead sponsor: University of North Texas Health Science Center; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Fort Worth, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: mHealth Intervention, Usual Care; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

Effects of a 4-week Raw, Plant-based Diet on Anthropometric and Cardiovascular Risk Factors

Lifestyle Interventions in Treatment-Resistant Hypertension

Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

Nicotinamide Riboside as an Enhancer of Exercise Therapy in Hypertensive Older Adults (The NEET Trial)

Cooking for Health Optimization With Patients

Splenic Embolization for Portal Hypertension

Effect of Occupational Therapy in Promoting Medication Adherence

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Measurement of High Blood Pressure Using Boppli

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Families on Track: A Digital Health Behavioral Intervention for Parents Seeking Treatment for Their Child With Obesity

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn

Postpartum Care in the NICU Multi-Site

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Better Understanding Patient Perspectives of an Educational Tool for Postpartum Hypertensive Patients

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Impact of Providing Medical Records in a Patient-Centered, Community Pharmacy Based, HIV Care Model (HIV-MOI)

The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study